Two main facts have to be taken into consideration: (i) that Ki67 is a tumor marker with different roles expressed during the whole cell cycle (except G0) [45], and (ii) that irinotecan targets DNA topoisomerase I, disrupting DNA synthesis and cell replication [46]. This evidence concerns the gene TOP1 and neoplasm.